Publications by Wim Van Criekinge.

2020

The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality
J. Delanghe, M. De Buyzere, S. De Bruyne, W. Van Criekinge and M. Speeckaert
(2020) ANNALS OF ONCOLOGY, 31,

A urine based genomic assay to triage patients with hematuria for cystoscopy
K. van Kessel, J. de Jong, A. Ziel-van der Made, H. Roshani, S. Haensel, J. Wolterbeek, E. Boeve, E. Oomens, N. van Casteren, M. Krispin, J. Boormans, E. Steyerberg, W. Van Criekinge and E. Zwarthoff
(2020) JOURNAL OF UROLOGY, 204,

Validation of a 2-gene mRNA urine test for the detection of >= GG2 prostate cancer in an opportunistic screening population
J. Rubio-Briones, A. Borque-Fernando, L. Esteban, J. Mascaros, M. Ramirez-Backhaus, J. Casanova, A. Collado, C. Mir, A. Gomez-Ferrer, A. Wong, F. Aragon, A. Calatrava, J. Lopez-Guerrero, J. Groskopf, J. Schalken, W. Van Criekinge and J. Dominguez-Escrig
(2020) PROSTATE, 80,

Underestimated effect of intragenic HIV-1 DNA methylation on viral transcription in infected individuals
S. Kint, W. Trypsteen, W. De Spiegelaere, E. Malatinková, S. Kinloch-de Loes, T. De Meyer, W. Van Criekinge and L. Vandekerckhove
(2020) CLINICAL EPIGENETICS, 12, 36

2019

MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide : a pooled analysis of four clinical trials
M. Hegi, E. Genbrugge, T. Gorlia, R. Stupp, M. Gilbert, O. Chinot, L. Nabors, G. Jones, W. Van Criekinge, J. Straub and M. Weller
(2019) CLINICAL CANCER RESEARCH, 25,

PROTEOFORMER 2.0 : further developments in the ribosome profiling-assisted proteogenomic hunt for new proteoforms
S. Verbruggen, E. Ndah, W. Van Criekinge, S. Gessulat, B. Kuster, M. Wilhelm, G. Menschaert and P. Van Damme
(2019) MOLECULAR & CELLULAR PROTEOMICS, 18,

Cost-effectiveness of SelectMDx for prostate cancer in four European countries : a comparative modeling study
T. Govers, D. Hessels, V. Vlaeminck-Guillem, B. Schmitz-Draeger, C. Stief, C. Martinez-Ballesteros, M. Ferro, A. Borque-Fernando, J. Rubio-Briones, J. Sedelaarll, W. Van Criekinge and J. Schalken
(2019) PROSTATE CANCER AND PROSTATIC DISEASES, 22,

Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy
A. Haese, G. Trooskens, S. Steyaert, D. Hessels, M. Brawer, V. Vlaeminck-Guillem, A. Ruffion, D. Tilki, J. Schalken, J. Groskopf and W. Van Criekinge
(2019) JOURNAL OF UROLOGY, 202,

Clinically significant prostate cancer diagnosed using a urinary molecular biomarker-based risk score : two case reports
P. Minnee, D. Hessels, J. Schalken and W. Van Criekinge
(2019) BMC UROLOGY, 19, 124

Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men
R. Waterhouse, L. Van Neste, K. Moses, C. Barnswell, J. Silberstein, M. Jalkut, R. Tutrone, J. Sylora, R. Anglade, M. Murdock, Z. Shiffman, T. Vandenberg, N. Shah, M. Carter, M. Krispin, J. Groskopf and W. Van Criekinge
(2019) UROLOGY, 128,